Table 4.

Table summarising priority level recommendations for management of urothelial cancers during COVID-19 pandemic

	Surgery	Radiation therapy	Systemic treatment
Priority level 1		•Radical radiotherapy with Radiosensitisation
Priority level 2	•Radical Cystectomy		•Neoadjuvant chemotherapy for small cell cancer of bladder
Priority level 3			•Adjuvant chemotherapy post-nephro-ureterectomy (pT2–T4 pN0–N3 M0/pTany N1–3 M0)
Priority level 4		•Palliative radiotherapy for bleeding or local control	•Neoadjuvant chemotherapy for urothelial MIBC •Adjuvant chemotherapy post-radical cystectomy for urothelial MIBC •First line systemic treatment for metastatic urothelial cancer of bladder •First line systemic treatment for metastatic small cell cancer of bladder •Adjuvant chemotherapy post-radical cystectomy •Neoadjuvant chemotherapy for adenocarcinoma cancer of bladder •Second line immune therapy treatment for metastatic urothelial cancer of bladder
Priority level 5
Priority level 6			•Neoadjuvant/adjuvant chemotherapy for squamous cell cancer of bladder •First line systemic treatment for metastatic adenocarcinoma cancer of bladder •Second/third line chemotherapy treatment for metastatic urothelial cancer of bladder

Abbreviation: MIBC – muscle invasive bladder cancer.